Suchergebnisse - "Lauseker, Michael"

PubPharm (5)

1

Survival with chronic myeloid leukaemia after failing milestones

enthalten in: Leukemia | 2023

von Lauseker, M. | Hehlmann, R. | Hochhaus, A. | +1

CommentIn: Leukemia. 2023 Oct 5;:. - PMID 37798329

2

Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase

enthalten in: Journal of cancer research and clinical oncology | 2014

von Lauseker, M. | Hanfstein, B. | Haferlach, C. | +11

3

Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib

enthalten in: Haematologica | 2014

von Hanfstein, B. | Lauseker, M. | Hehlmann, R. | +27

4

Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib : results from the randomized CML-study IV

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2014

von Hehlmann, R. | Müller, M. | Lauseker, M. | +29

CommentIn: J Clin Oncol. 2014 Feb 10;32(5):471-4. - PMID 24297955

5

Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators : results from the randomized CML study IV

enthalten in: Annals of hematology | 2014

von Kalmanti, L. | Saussele, S. | Lauseker, M. | +25

1
[1]